- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01697436
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
November 1, 2016 updated by: Hoffmann-La Roche
A Bioequivalence Study of Ribavirin Oral Solution (RO0209963) Versus the Reference Ribavirin Tablets (Copegus) Following Oral Administration in Healthy Adult Subjects
This four-period, single-center, open-label, single-dose, randomized, cross-over study will assess the bioequivalence and safety of an oral solution of Copegus (ribavirin) compared to a Copegus tablet in healthy adult volunteers.
Volunteers will be randomized to one of four sequences in which they will receive the treatment under fed and under fasted conditions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult healthy volunteers
- Able to participate and willing to give informed consent and comply with the study restrictions.
- Negative urine pregnancy test (for women of childbearing potential) documented at screening and within the 24-hour period prior to each dose of test drug
- All male subjects with female partners of childbearing potential must agree to use two reliable forms of contraception, one of which must be a physical barrier method, during the study and for 6 months thereafter
- Female subjects must be postmenopausal or surgically sterile or they must agree to use two reliable forms of contraception one of which must be a physical barrier method, during treatment and for 6 months thereafter
- Body mass index (BMI) <30 kg/m2
Exclusion Criteria:
- Pregnant or lactating women and male partners of females who are pregnant or lactating
- Positive test for drugs of abuse at screening and within the 24-hour period prior to each dose of test drug.
- History (within 3 months of screening) of alcohol consumption exceeding 2 standard units per day on average (1 standard unit = 10 grams of alcohol). Alcohol consumption will be prohibited at least 48 hours before screening and from at least 48 hours before Day -1 through the end of the study
- Confirmed systolic blood pressure (SBP) > 140 or < 90 mm Hg, and diastolic blood pressure (DBP) > 90 or < 50 mm Hg
- Resting pulse rate > 90 or < 45 beats per minute
- History or symptoms of any significant disease including (but not limited to) hematological, neurological, psychiatric, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder
- History of active malignancy within the last 5 years, with the exception of localized or in situ carcinoma of the skin (e.g., skin basal or squamous cell carcinoma)
- Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening
- Use of any medications (prescription or over-the-counter, vitamin, mineral, herbal, and dietary supplements within 7 days, or less than 5 half-lives (whichever is longer) prior to randomization. Exceptions are acetaminophen (up to 2 g/day), ibuprofen (up to 1 g/day), and hormonal contraceptives.
- Clinically significant abnormalities in laboratory test results
- Participation in an investigational drug study within 60 days or in an investigational device study within 30 days prior to screening
- Donation of blood over 500 mL from 3 months prior to screening until the end of the study; donation of plasma from 7 days prior to screening until the end of the study
- Concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study
- Smoker of more than 10 cigarettes per day prior to screening or use of tobacco products equivalent to more than 10 cigarettes per day
- Clinically significant abnormalities in the pre-dose resting electrocardiograms
- Any confirmed significant allergic reactions against RBV or known or potential allergy or hypersensitivity to the non-active ingredients of the study drugs (non-active hay fever is acceptable)
- Individuals receiving ribavirin therapy within 6 months prior to study initiation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Crossover Period 1
|
tablet under fed condition
tablet under fasted condition
oral solution under fed condition
oral solution under fasted condition
|
Experimental: Crossover Period 2
|
tablet under fed condition
tablet under fasted condition
oral solution under fed condition
oral solution under fasted condition
|
Experimental: Crossover Period 3
|
tablet under fed condition
tablet under fasted condition
oral solution under fed condition
oral solution under fasted condition
|
Experimental: Crossover Period 4
|
tablet under fed condition
tablet under fasted condition
oral solution under fed condition
oral solution under fasted condition
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics: area under the plasma concentration time curve
Time Frame: Periods 1-4: Predose and up to 192 hours post-dose
|
Periods 1-4: Predose and up to 192 hours post-dose
|
Pharmacokinetics: maximum plasma concentration
Time Frame: Periods 1-4: Predose and up to 192 hours post-dose
|
Periods 1-4: Predose and up to 192 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety: incidence of adverse events
Time Frame: Approximately 16 weeks
|
Approximately 16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
September 28, 2012
First Submitted That Met QC Criteria
September 28, 2012
First Posted (Estimate)
October 2, 2012
Study Record Updates
Last Update Posted (Estimate)
November 2, 2016
Last Update Submitted That Met QC Criteria
November 1, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BP28307
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
International Bio serviceNot yet recruitingHealthy Volunteer
-
International Bio serviceNot yet recruiting
-
Disc Medicine, IncRecruiting
-
National Cancer Institute (NCI)Recruiting
-
National Institute on Deafness and Other Communication...Recruiting
-
National Institute of Allergy and Infectious Diseases...RecruitingHealthy VolunteerUnited States
-
National Institute of Mental Health (NIMH)Recruiting
-
University Hospital, GrenobleCompletedHealthy VolunteerFrance
-
AbbVieActive, not recruitingHealthy VolunteerUnited States
-
Hospices Civils de LyonCompleted
Clinical Trials on ribavirin [Copegus]
-
Hoffmann-La RocheCompletedHealthy VolunteerMexico
-
Conatus Pharmaceuticals Inc.Completed
-
Karolinska InstitutetThe Swedish Research Council; Hoffmann-La RocheCompletedChronic Hepatitis C | Human Immunodeficiency VirusSweden
-
Teva Pharmaceuticals USACompleted
-
Mashhad University of Medical SciencesCompleted
-
Hoffmann-La RocheCompletedHepatitis C, ChronicUnited States, Puerto Rico
-
Baqiyatallah Medical Sciences UniversityShahid Beheshti University of Medical Sciences; Guilan University of Medical... and other collaboratorsCompletedHemophilia | Hepatitis CIran, Islamic Republic of
-
Hoffmann-La RocheCompleted
-
Teva Pharmaceuticals USACompleted
-
Kirby InstituteCompletedDAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (DARE-C II)Hepatitis CAustralia, New Zealand